

*Not elect*  
*But*  
for 5–10 minutes to 2 hours with cell suspensions containing the target cells at 0°C to 25°C, optionally followed by a per se known enrichment procedure, and evaluation of the target cell rosettes microscopically and/or by suitable visualizing or imaging devices.

*(M C3)*  
6. (Amended) Method according to claim 7 [5], characterized in that the particles used in the method are coated with [ligands/]antibodies directed against the receptors/antigens listed in Table 1.

*B2*  
7. (Amended) Method according to claim 1 [5], characterized in that the particles used in the method are coated with antibodies directed to tumor associated antigens.

*B3*  
13. (Amended) Use according to claim 1 [12], wherein the adhesion molecules are E-cadherin, the growth factor receptors are EGFr, c-erbB2, IL-2 receptor, TNF receptor, the carcinoma markers are EGP2, MUC1, MUC2 & 3, PSA, PSM, GA733.2, TAG 72, 15-3 epitope, ovarian carcinoma CA-125 epitope, the carbohydrate antigens are LeY, CEA, 15-3 epitope, the melanoma antigens are HMW 250000, gp 75/TRP-1, p95, MAG 1, 2, 3, the sarcoma antigens are TP 1 and TP 3 epitopes, the glioma antigens such as Mel-14 epitope, apoptosis associated markers are Fas FasL, p75, the motility related markers are KAT-1, AMF, the proliferation associated antigens are gp120, the differentiation associated markers are MUC 18, TA99, the drug resistance markers are MDR, MRP, the angiogenesis associated antigens are VEGFr, bFGF, [the chemokine receptors are CCR, CXCR,] the invasion-related markers are uPAR, uPA, PAI-I, TIMP1 & 2, MMP9, stromelysins, and the other antigens are cathepsin D and par-human epitope.

#### REMARKS

Without acquiescing to the statements made therein, Applicants hereby elect the antibodies species, and tumor associated antigens as a subspecies, with traverse. Applicants traverse the Examiner's request for election as they do not necessarily wish to be constrained to the Examiner's rationale for requesting the election.